This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Mindset Pharma is a drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders.
Founded by serial entrepreneurs and domain experts in drug development and medicinal chemistry and based in Toronto, Canada, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely.
Stock Performance
Mindset Pharma News 36 articles
- Otsuka Pharmaceutical to Acquire Mindset Pharma
- Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds
- Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
- Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics
- Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
- Reunion Neuroscience Files Lawsuit Against Mindset Pharma
- Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership
- Mindset Pharma to Participate in Upcoming Conferences in December 2022
- Mindset Pharma CEO, James Lanthier Issues Letter to Shareholders
- Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
- Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate
- Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences
- Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio
- Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
- Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries
- Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds
- Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
- Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
- Mindset Pharma Receives Notice of Allowance for Patent Application for Psilocin Derivatives
- Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its DMT and 5-MeO-DMT Drug Candidate Compounds
- Mindset Pharma Enters Manufacturing Agreement to Produce Next-Generation Psilocybin Drug Candidate, MSP-1014
- Mindset Pharma Recaps 2021 Milestones and Highlights
- Mindset Pharma Announces Filing of International Patent Application Covering its Family 3 “Microdose” Compounds
- Mindset Pharma Announces Further Preclinical Results for its 5-MeO-DMT-Inspired Drug Candidate.
- Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates
- Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program
- Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine
- Mindset Pharma Announces Positive Preclinical Results of DMT Compounds
- Mindset Pharma Announces Closing of $7.5 Million Bought Deal Public Offering
- Mindset Pharma Added to North American Psychedelics Index
- Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds
- Mindset Further Expands Portfolio of Psychedelic Drug Candidates with Third U.S. Provisional Patent Application; 50 Total New Psychedelic Patent-Pending Compounds Synthesized
- Mindset Pharma to Commence Trading on the CSE on December 23, 2020 Under the Symbol “MSET”
- Mindset Pharma Inc. and North Sur Complete Combination; North Sur Changes Name to Mindset Pharma Inc.
- Mindset Pharma Announces Promising Test Results of its Novel and Proprietary Psilocybin-Inspired Compounds
- Mindset Pharma Announces Filing of Groundbreaking Psilocybin Synthesis Patent